COVID-19 May Increase IVIG-Resistance in Kids Prior to Developing Kawasaki Disease
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
Moderna’s Flu Vaccine Shows Positive Late-Stage Trial Results
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
COVID-19-Influenza Combination and Standalone Influenza Vaccines Generated a Strong Immune Response
In a late-stage trial, Novavax’s experimental COVID-19-influenza combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccines generated a strong immune response in adults aged 65 and older, similar to already approved vaccines against the viruses.
Novavax’s COVID-19 Vaccine Approved for Older Adults and At-Risk Individuals
After a six-week delay, the U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but only for people 65 and older and those 12 years and older who have at least one underlying condition, such as asthma, diabetes, lung disease, obesity and pregnancy, that puts them at higher risk of severe illness.
Combination Flu and COVID-19 Vaccine Prompts Immune Response in Older Adults
A recent study of Moderna’s combination influenze (flu) and COVID-18 vaccine, mRNA-1083, found that it induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all four influenza strains (among those ages 50 to 64 years), the three clinically relevant influenza strains (among those aged 65 years and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.
COVID-19 May Increase Kawasaki Disease Risk
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease (KD).
COVID-19 Vaccine May Reduce Risk of Developing Long COVID
A new study published in the journal Vaccine, shows that receiving a COVID-19 vaccine could reduce the risk of developing long COVID if it’s administered five months before an infection.
Study Finds Link Between COVID-19 and Autoimmunity
A population-based study conducted by researchers from the Republic of Korea found a significantly higher risk of developing autoimmune and autoinflammatory conditions, such as rheumatoid arthritis (RA), lupus, Crohn’s disease, and alopecia, among individuals who had COVID-19, with risks particularly elevated for those with severe cases, Delta variant infections and those who were unvaccinated.
Nasal Swab May Predict Severity of COVID-19
New research suggests autoantibodies in the nasal cavity may predict the severity of COVID-19 disease.
FDA Approves First Over-the-Counter Combo Flu and COVID Test Outside of Emergency Use
The U.S. Food and Drug Administration (FDA) has authorized the first over-the-counter combination COVID-19 and influenza test, the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, outside of emergency use.
